Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Pediatric Endocrinology and Metabolism

Editor-in-Chief: Kiess, Wieland

Ed. by Bereket, Abdullah / Darendeliler, Feyza / Dattani, Mehul / Gustafsson, Jan / Luo, Fei Hong / Mericq, Veronica / Toppari, Jorma


IMPACT FACTOR 2018: 1.239

CiteScore 2018: 1.22

SCImago Journal Rank (SJR) 2018: 0.507
Source Normalized Impact per Paper (SNIP) 2018: 0.562

Online
ISSN
2191-0251
See all formats and pricing
More options …
Volume 24, Issue 5-6

Issues

Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves’ disease: efficacy and adverse reactions during initial treatment and long-term outcome

Hirokazu Sato / Masanori Minagawa / Nozomu Sasaki / Shigetaka Sugihara
  • Department of Pediatrics, Tokyo Women’s Medical University Medical Center East, Tokyo, Japan
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Itsuro Kazukawa / Kanshi Minamitani / Kunio Wataki / Susumu Konda / Hiroaki Inomata / Kazunori Sanayama
  • Sunrise Children’s Clinic, Funabashi, Japan
  • Department of Pediatrics, Narita Red Cross Hospital, Narita, Japan
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Yoichi Kohno

Abstract

Objective: The aim of this study was to compare the efficacy and adverse reactions during initial treatment and long-term outcome between children and adolescents with Graves’ disease (GD) treated with propylthiouracil (PTU) and those treated with methimazole (MMI).

Design, setting and participants: Retrospective and collaborative study. Children and adolescents with GD were divided into group M (MMI: n=64) and group P (PTU: n=69) and into four subgroups by initial dose: group M1 (<0.75 mg/kg of MMI, n=34), group M2 (≥0.75 mg/kg, n=30), group P1 (<7.5 mg/kg of PTU, n=24) and group P2 (≥7.5 mg/kg, n=45).

Main outcome measures: The duration for normalization of serum T4 on initial treatment, the incidence of adverse effects for one year and outcomes at 10 years after were compared.

Results: Mean durations for normalization of T4 (±SD) were 1.7±1.0 months in group M and 2.3±2.4 in group P [not significant (NS)], while the mean duration in group P1 (3.1±3.3) was significantly longer than those in the other subgroups (M1: 1.9±1.2; M2: 1.4±0.7; P2; 1.7±1.3). No major adverse reaction was observed. Minor adverse effects occurred in 25.0% of cases in group M and 31.9% in group P (NS). The incidence in group P2 (44.4%) was significantly higher than those in group M1 (20.6%) and group P1 (8.3%). Remission rates did not differ between the MMI-treated group (35.0%, n=20) and PTU-treated group (50.0%, n=40).

Conclusions: PTU may not be suitable for initial use in children and adolescents with GD, even with the risk of major adverse reactions such as liver failure excluded.

Keywords: adolescence; anti-thyroid drugs; children; Graves’ disease; methimazole; propylthiouracil

About the article

Corresponding author: Hirokazu Sato, Sunrise Children’s Clinic, Nakayama Medical Square 1F, 4-22-10 Motonakayama, Funabashi, Chiba 273-0035, Japan Phone: +81 47 3338222, Fax: +81 47 3332733


Published in Print: 2011-06-01


Citation Information: Journal of Pediatric Endocrinology and Metabolism, Volume 24, Issue 5-6, Pages 257–263, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: https://doi.org/10.1515/jpem.2011.194.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
F. Azizi and R. Malboosbaf
Journal of Endocrinological Investigation, 2019
[2]
Fereidoun Azizi and Ramin Malboosbaf
Thyroid, 2017, Volume 27, Number 10, Page 1223
[3]
LIN LIU, HONGWEN LU, YANG LIU, CHANGSHAN LIU, and CHU XUN
Experimental and Therapeutic Medicine, 2016, Volume 11, Number 4, Page 1453
[4]
Ana Luiza Maia, Rafael S. Scheffel, Erika Laurini Souza Meyer, Glaucia M. F. S. Mazeto, Gisah Amaral de Carvalho, Hans Graf, Mario Vaisman, Lea M. Z. Maciel, Helton E. Ramos, Alfio José Tincani, Nathalia Carvalho de Andrada, and Laura S. Ward
Arquivos Brasileiros de Endocrinologia & Metabologia, 2013, Volume 57, Number 3, Page 205
[5]
Kanshi Minamitani, Hirokazu Sato, Hidemi Ohye, Shohei Harada, and Osamu Arisaka
Clinical Pediatric Endocrinology, 2017, Volume 26, Number 2, Page 29
[6]
Kie Yasuda, Yoko Miyoshi, Makiko Tachibana, Noriyuki Namba, Kazunori Miki, Yukiko Nakata, Toru Takano, and Keiichi Ozono
Clinical Pediatric Endocrinology, 2017, Volume 26, Number 1, Page 1
[7]
T Arrigo, PM Cutroneo, M Vaccaro, D Impollonia, V Squadrito, A Mecchio, C Salpietro, and D Altavilla
International Journal of Immunopathology and Pharmacology, 2016, Volume 29, Number 4, Page 707
[8]
Shona Rabon, Amy M. Burton, and Perrin C. White
Clinical Endocrinology, 2016, Volume 85, Number 4, Page 632
[9]
Anam Akmal and Jacqueline Kung
Expert Opinion on Drug Safety, 2014, Volume 13, Number 10, Page 1397
[10]
Hidemi Ohye, Akinobu Minagawa, Jaeduk Yoshimura Noh, Koji Mukasa, Yo Kunii, Natsuko Watanabe, Masako Matsumoto, Miho Suzuki, Ai Yoshihara, Koichi Ito, and Kunihiko Ito
Thyroid, 2014, Volume 24, Number 2, Page 200
[11]
Panagiotis Anagnostis, Fotini Adamidou, Stergios A. Polyzos, Simoni Katergari, Eleni Karathanasi, Chrisanthi Zouli, Athanasios Panagiotou, and Marina Kita
Endocrine, 2013, Volume 44, Number 2, Page 448
[12]
Manish Kumar Gupta, Dev Bukhsh Singh, Rohit Shukla, and Krishna Misra
OMICS: A Journal of Integrative Biology, 2013, Volume 17, Number 11, Page 584

Comments (0)

Please log in or register to comment.
Log in